Hank Harris turned to new technology to create Harrisvaccines and along the way he is developing a rapidresponse tool for animal disease outbreaks

Hank Harris turned to new technology to create Harrisvaccines, and along the way he is developing a rapid-response tool for animal disease outbreaks.

2015 Pork Master: Hank Harris, Vaccine company entrepreneur

The Masters of the Pork Industry are a very special, handpicked group of pork industry leaders. These are their stories. The Masters share their personal stories and philosophies about life, their careers in the pork industry and their visions for the future. They are professionals, entrepreneurs and family-based pork industry enthusiasts whose dedication and wisdom are sure to inspire young and old as they tackle the challenges and opportunities that lie ahead in an ever-changing global pork industry.

It’s not the first time Harris has been featured in the magazine; in 2005 Harris was named as one of the 50 top contributors to the swine industry. “That’s the year I started this company,” Harris notes. And that’s important in his being named a 2015 Pork Master. After what was already an influential career, Harris wasn’t finished as he got Harrisvaccines started. Sitting in Hank Harris’ office in Ames, Iowa, it’s not hard to picture him lecturing to a new class of young veterinary wannabes interested in being a part of the world of animal medicine. Yet he’s speaking to National Hog Farmer at Harrisvaccines, a firm innovating the way viral diseases are treated.

As Harrisvaccines enters its 10th year, the firm is still celebrating a major win. Last year the company licensed the first vaccine for the treatment of porcine epidemic diarrhea virus, but that success came after more than a decade of work in developing a new approach to viruses. Perhaps the bigger surprise to Harris’ friends happened back when he made the switch from bacteriology to virology as his specialty.

“I began working in virology to tackle PRRSV [porcine reproductive and respiratory syndrome virus],” Harris says. “That was the direction I felt I needed to go, and that’s what led me to the technology we’re using today.”

 

That road wasn’t a smooth trip on fresh pavement. For Harris, who has always had an entrepreneurial spirit, creating a new way to take on PRRSV meant financing research into novel ways to tackle troublesome and difficult diseases, and blazing a path for a different approach to vaccine development.

Harrisvaccines is a pioneer in the animal vaccine business using an approach called RNA particle technology. Researchers in the firm’s lab never get near the live virus for anything they’re treating. Instead, a diagnostic lab just sends along an electronic map of a key part of the virus, and from that Harrisvaccines can start to build a vaccine. (See “Designing a vaccine.”)

Starting on the farm

Harris grew up on a farm not far from Ames, working with all kinds of animals through 4-H and FFA projects. “We had them all,” he chuckles, looking back. “We were a purebred Duroc breeder; we had Angus cattle, rabbits and sheep.” Back in the 1950s, that kind of diversification was common for farms, and from that Harris gained a respect for animal health and husbandry.

Harris was always going to go to Iowa State, but back then the idea of leaving the farm for college was still novel. He recalls his father being chastised by other family members for sending Hank and his brother to college. “He was just adamant that we would go to college, didn’t have the money necessarily, but that we were going to college,” Harris recalls. “It was fantastic … there wasn’t any question.”

But it appears pigs would get most of his attention. Harris earned his doctor of veterinary medicine degree from Iowa State University, and his work as a student with Bill Switzer led him down a research path — including a research program when he graduated.

“I practiced in the field for three weeks, once,” he recalls. “A classmate asked me to cover for him for three weeks, and I helped out his practice near Mount Pleasant, Iowa. I got the practice fever out of me then.”

He laughs easily when he tells the story of his “fieldwork,” but it was his work in the lab and creating new ways to protect pigs that was more interesting; that has led to some industry-leading discoveries. In the 1970s, Harris is credited with discovering and naming the cause of swine dysentery, a debilitating herd disease that was a global problem. Harris’ research team at Iowa State discovered the root cause of the disease, Brachyspira hyodysenteriae — a nasty bug that causes heavy herd losses.

The ISU research coincided with work at Cambridge University that made a similar finding and validated the work at the time. Identifying the problem was the first step in finding prevention measures to help producers protect herds.

Yet Harris had an entrepreneurial bent. While research was his focus, he looked off campus to the idea of creating his own business. He was one of the founders and a CEO of NOBL Laboratories. The business grew to be a leader in the development and manufacture of novel swine vaccines. That work included the development of highly effective oral ileitis and intranasal atrophic rhinitis vaccines. The work caught the attention of another company that was growing its U.S. business — Boehringer Ingelheim Vetmedica. BIVI acquired NOBL Labs in 1997. By then Harris was already on to other things.

Harris later joined PIC — originally known as the Pig Improvement Co. He set up the company’s health program and was involved with the firm’s innovative system of swine breeding and genetics. He’s also credited with helping perfect the PIC multiple-site production system — a process that has been adopted globally.

Eventually, Harris moved up to become a vice president of PIC USA. “They actually brought weekly recordkeeping to the United States,” Harris recalls. “When they came in during the early 1970s, the idea of once a week actually doing an inventory of the deads by age group, and calculating your costs, whatever the expenses were that week and whatever the income was that week … those were not common concepts in the industry at that time.”

He notes that England, back in the 1970s, was already ahead of the U.S. in numbers like pigs per sow per year and management approaches. When he joined, PIC was growing, and Harris was part of that as the firm expanded in the 1980s.

By the turn of the century, Harris had an impressive resume. Looking back, he says that perhaps what has worked for him is that he gained the mindset of the entrepreneur. “An entrepreneur is a person who is always seeking solutions, you know, finding an interesting problem and doing whatever it takes to find the solution,” Harris says. “I’m not inhibited by not knowing something about a technology or an area of interest. Just dive in and do it.”

That problem-solving attitude even brought on a significant course change in his career in the early 2000s. “I switched to shrimp in 2002 and switched to viruses in 2003. And [up until then] I’d spent my whole career as a microbiologist working on bacteria,” he says. “That may not translate well, but that’s actually … my virology friends couldn’t believe it.”

And why the change? “It was PRRSV; that’s the best explanation,” he says.

The road to virology started a decade earlier when Harris returned to the ISU faculty, and he had to refresh his knowledge of molecular biology — a fast-growing science that has led to significant genetic discoveries. “I guess the more I learned about molecular aspects and thought about PRRSV, it just drove me” toward virology, he says.

Part of that move also involves the simplicity of viruses. Bacteria are complex organisms, but viruses are actually quite simple, Harris says. And that’s true of the cornerstone of the vaccine work he’s involved in now.

“Even the technology we use now to make vaccines, the virus we use that it’s derived from is a very simple virus molecularly speaking. That’s why it’s so easy to work with,” Harris says. “It’s why we’re able to make a new vaccine so quickly.”

A simple alphavirus is the base of what Harrisvaccines does today. The simple virus allows researchers to drop out one RNA for another and then replicate it for later creation as a vaccine. It’s the RNA that creates the immune, and cellular, response in the animal to fight off the disease. The key is to identify the right strand of RNA to prevent/treat the disease. And there’s the rub.

“We still haven’t found the solution for PRRSV,” Harris laments. “I think that’s really amazing that you start a company specifically to solve the major problem in the industry, and we’re still working on it, and yet the company has been successful, because we took technology that we thought would work for PRRSV and we were able to find that it was very useful for other diseases.”

As for PEDV? That was actually easier. “We identified the strain from China and identified the right RNA to treat for the disease,” Harris says. “PEDV is a highly conserved virus, which means that the part we chose is conserved across different strains of the virus.”

That “conservation” means that the Harris’ product doesn’t have to be customized to treat the disease in a specific herd. The PEDV vaccine works no matter the origin of the PEDV strain in a specific herd.

Herd specificity and new technology

It’s that herd specificity that first helped Harrisvaccines get through some regulatory hurdles when it started out. The idea of creating vaccines using particle RNA, which provides the ability to develop a vaccine in as little as four to six weeks, was a new idea to regulators. Normally, a vaccine has to go through a wide array of regulatory hurdles to get to market.

Harris notes that visitors to the facility are surprised by its size. While it has expanded space recently, the preconceived image of the company differs from what you see when you get to the Ames plant. “We use one technology to create a variety of vaccines.”

Regulators were also not up to speed on the new concept, which for a fledgling company can be a challenge, but the firm started generating income by selling its products under rules associated with autogenous vaccines (those mixed by the local veterinarian for a herd-specific problem). Using those rules with the USDA built the ground work.

Harris chronicles the process of working with regulators, lobbying the USDA and keeping up pressure. In 2012, Harrisvaccines became the first company to get full USDA approval for its H3N2 swine influenza vaccine, RNA. This was a proof of the concept that the vaccine platform was safe and efficacious. At the same time, researchers were applying the technology to new diseases. The arrival of PEDV showed that this new RNA technology could make a difference. Today, the Harrisvaccines’ PEDV vaccine is conditionally licensed by the USDA.

The company is also developing a wide range of other vaccines for use in the equine, cattle, poultry, canine and even shrimp markets. Harris got interested in shrimp — commercial shrimp have a range of potential diseases — as part of his move to viruses, too. “Shrimp are fascinating,” he notes.

Looking ahead

Harris, now 71, is looking to the future. “I’m looking toward retirement,” he says. “I want the company to go on, and I think we’re set up for that.” He acknowledges that the firm will need more investment if it is to grow, a constant challenge for a startup.

His sons are involved in the firm, which is a source of pride for Harris. And he feels his young team of researchers is well on its way to working out solutions to a wide range of problems, including foot-and-mouth disease and other herd issues.

Hank Harris is a pork industry leader because he’s always looking for a solution to the next problem. That lays the groundwork for a solid future for Harrisvaccines, and perhaps an eventual solution for PRRSV. It has also poised Harrisvaccines to take on newer emerging diseases in other species. Avian and canine influenza are plastered in the headlines as of late, and Harrisvaccines has already begun working on candidate vaccines for both the poultry and companion animal industries.

“This is just what our production model is meant for, to rapidly respond to new diseases faster than anyone else,” Harris notes.

Hide comments

Comments

  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Publish